TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31366999

Group type: EXPERIMENTAL
Intervention: Home weight control programme
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Community weight control programme
Number of subjects: 409

Group type: COMPARATOR
Intervention: Standard written advice (control)
Number of subjects: 409
Study: 30303664

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dalargin therapy (2 mg/day for 10 days, 3 courses during 3 months)
Number of subjects: 123
Study: 25566706

Group type: COMPARATOR
Intervention: Aprotinin (Group A; n = 24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Group B; n = 26)
Number of subjects: 50
Study: 23418000

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 14
Study: 19514183

Group type: EXPERIMENTAL
Intervention: needle‐rolling therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: clonopin (control)
Number of subjects: 180
Study: 16772810

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/d (increased to mean 10.55 mg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Olanzapine 20 mg/d (fixed dose)
Number of subjects: 51
Study: 15618849

Group type: EXPERIMENTAL
Intervention: Music therapy during colonoscopy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 118
Study: 11819728

Group type: COMPARATOR
Intervention: Conservative treatment (Group A)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Hepatic artery ligation (HAL) and/or hepatic artery infusion (HAI) (Group B)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Removal of HCC with PVTT (Group C)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Transcatheter hepatic arterial chemoembolization (TACE) or HAI and/or portal vein infusion (PVI) after operation (Group D)
Number of subjects: 147
Study: 9247243

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (blast type)
Number of subjects: 14
Study: 7509784

Group type: EXPERIMENTAL
Intervention: High Dose Trasylol (Hammersmith dosage: 6 x 10(6) KIU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low Dose Trasylol (half of Hammersmith dosage)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Dose Trasylol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low Dose Trasylol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Dose Trasylol and Low Dose Trasylol
Number of subjects: 120
Study: 2959236

Group type: EXPERIMENTAL
Intervention: Captopril (average dosage 265 mg/d, range 150-300 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Minoxidil (average dosage 19.6 mg/d, range 7.5-30 mg)
Number of subjects: 25
Study: 31948461

Group type: COMPARATOR
Intervention: Aspirin (n = 40)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Rosuvastatin (n = 48)
Number of subjects: 130
Study: 29866645

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study: 27501153

Group type: EXPERIMENTAL
Intervention: MitoQ supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 0
Study: 25046515

Group type: EXPERIMENTAL
Intervention: Citicoline-caffeine beverage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23533254

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine (0-100 µg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (0-8.8 mg)
Number of subjects: 11
Study: 20592725

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two 510 mg doses administered 24 h apart)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 17483103

Group type: EXPERIMENTAL
Intervention: 4-month lifestyle program focusing on weight loss, diet, and exercise
Number of subjects: 241
Study: 16841666

Group type: EXPERIMENTAL
Intervention: Insulin and multi-glycosides of tripterygii (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 0
Study: 11834754

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10493671

Group type: EXPERIMENTAL
Intervention: HLA-DMA*0104 in patients with SLE
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108
Study: 8545138

Group type: EXPERIMENTAL
Intervention: Methadone (custom-made capsules)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Methadone (suppositories)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hydromorphone (control)
Number of subjects: 37
Study: 1902052

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (ECA) 325 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6126475

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30151373

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26179466

Group type: EXPERIMENTAL
Intervention: BITE supervision
Number of subjects: 42

Group type: COMPARATOR
Intervention: DVB supervision
Number of subjects: 42
Study: 24154682

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily)
Number of subjects: 1
Study: 22088611

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Auditory commands to harm or kill the self
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Delusions with themes pertaining to the paranormal
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Delusions with references to celebrities
Number of subjects: 327
Study: 20166783

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18760125

Group type: EXPERIMENTAL
Intervention: Patient self-management (SM) skills training in combination with HF education
Number of subjects: 902

Group type: COMPARATOR
Intervention: HF education alone (control)
Number of subjects: 902
Study: 15973062

Group type: EXPERIMENTAL
Intervention: Oral ramosetron
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intravenous granisetron
Number of subjects: 56

Group type: COMPARATOR
Intervention: Dopamine D2 receptor-blocker (historical control)
Number of subjects: 56
Study: 12204841

Group type: EXPERIMENTAL
Intervention: Combination therapy with saquinavir soft gel, zalcitabine and zidovudine for 52 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Switching to nelfinavir, lamivudine and zidovudine for further 52 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High viral load and presence of RT mutations at baseline
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline viral load and development of genotypic mutations on therapy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Plasma saquinavir concentration < 50 mg/ml at 4 weeks
Number of subjects: 95
Study: 10663322

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonoperative regime
Number of subjects: 16
Study: 8803522

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg intravenously
Number of subjects: 12
Study: 1618070

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cisapride (2.5 mg and 5 mg)
Number of subjects: 10
Study: 6705640

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingually/buccally)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propantheline bromide (15 mg orally)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and propantheline bromide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31622374

Group type: EXPERIMENTAL
Intervention: 50 mg D-cycloserine (DCS)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 29220679

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 0
Study: 26908401

Group type: EXPERIMENTAL
Intervention: Edoxaban (high-dose edoxaban regimen - 60 mg daily; lower-dose edoxaban regimen - 30 mg daily) with SAPT (aspirin 92.5%)
Number of subjects: 4912

Group type: COMPARATOR
Intervention: Edoxaban (high-dose edoxaban regimen)
Number of subjects: 4912

Group type: EXPERIMENTAL
Intervention: Edoxaban (high-dose edoxaban regimen) with SAPT
Number of subjects: 4912

Group type: COMPARATOR
Intervention: Warfarin without SAPT
Number of subjects: 4912

Group type: EXPERIMENTAL
Intervention: Warfarin with SAPT
Number of subjects: 4912

Group type: COMPARATOR
Intervention: Edoxaban (lower-dose edoxaban regimen) without SAPT
Number of subjects: 4912

Group type: EXPERIMENTAL
Intervention: Edoxaban (lower-dose edoxaban regimen) with SAPT
Number of subjects: 4912
Study: 25089537

Group type: EXPERIMENTAL
Intervention: Weekly oral dose of 0.875 mg vitamin D₃ (vitD₃)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: TLR4L stimulation
Number of subjects: 129
Study: 22706941

Group type: EXPERIMENTAL
Intervention: 1-min stage duration
Number of subjects: 28

Group type: COMPARATOR
Intervention: 3-min stage duration
Number of subjects: 28

Group type: COMPARATOR
Intervention: 6-min stage duration
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 50% PPO with prior maximal incremental test
Number of subjects: 28

Group type: COMPARATOR
Intervention: 50% PPO without prior maximal incremental test
Number of subjects: 28
Study: 21120294

Group type: EXPERIMENTAL
Intervention: 3000 shocks at a rate of 60 impulses per minute
Number of subjects: 299

Group type: COMPARATOR
Intervention: 4000 shocks at 90 impulses per minute
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 3000 shocks at a rate of 60 impulses per minute for stones smaller than 10 mm
Number of subjects: 299

Group type: COMPARATOR
Intervention: 4000 shocks at 90 impulses per minute for stones smaller than 10 mm
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 3000 shocks at a rate of 60 impulses per minute for stones bigger than 10 mm
Number of subjects: 299

Group type: COMPARATOR
Intervention: 4000 shocks at 90 impulses per minute for stones bigger than 10 mm
Number of subjects: 299
Study: 18545061

Group type: EXPERIMENTAL
Intervention: 120 mg/day of extract of ginkgo biloba (EGb) for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 42
Study: 15706460

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Trimipramine
Number of subjects: 41
Study: 12595862

Group type: EXPERIMENTAL
Intervention: Soy protein (25 g daily for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10571339

Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No fluorescein angiography (FA)
Number of subjects: 100
Study: 8701398

Group type: EXPERIMENTAL
Intervention: Hirudin (10, 15 or 20 mg s.c. b.i.d.)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU s.c. t.i.d.)
Number of subjects: 148
Study: 1649267

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CE'P and MEC' regimens)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 128
Study: 6378303

Group type: EXPERIMENTAL
Intervention: Clomipramine (tricyclic antidepressant)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clorgyline (monoamine oxidase inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30777471

Group type: EXPERIMENTAL
Intervention: Resveratrol (400 mg) for 12-14 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Surgical removal of endometritic lesions
Number of subjects: 34
Study: 29722128

Group type: EXPERIMENTAL
Intervention: CNI-free everolimus regimen
Number of subjects: 497

Group type: COMPARATOR
Intervention: Standard CNI
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Low-exposure CNI with everolimus
Number of subjects: 497
Study: 27908954

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated dressings
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 100
Study: 25006719

Group type: EXPERIMENTAL
Intervention: Dupilumab monotherapy (4-week trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab monotherapy (12-week trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab plus topical glucocorticoids (4-week trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus topical glucocorticoids (4-week trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 21345681

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee replacement (UKA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: TKA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: UKA
Number of subjects: 56
Study: 20211113

Group type: EXPERIMENTAL
Intervention: Lipid extraction and soaking in water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no lipid extraction or soaking)
Number of subjects: 0
Study: 17961725

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (SCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmyeloablative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous mobilized peripheral blood stem cell (PBSC) transplantation
Number of subjects: 0
Study: 18290397

Group type: EXPERIMENTAL
Intervention: High-dose intravenous deferoxamine (130 mg/kg per day over 10-14 hours for 5 consecutive days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose intravenous deferoxamine
Number of subjects: 15
Study: 15471837

Group type: EXPERIMENTAL
Intervention: 99mTc‐pertechnetate per‐rectal portal scintigraphy (PPS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (clinically well children)
Number of subjects: 22
Study: 11387540

Group type: EXPERIMENTAL
Intervention: Self-help kit and fully covered benefits for OTC nicotine replacement therapy (NRT) gum and patch, and participation in a group behavioural cessation programme with no patient cost sharing
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Self-help kit (video and pamphlet)
Number of subjects: 1204
Study: 9263614

Group type: EXPERIMENTAL
Intervention: Ipriflavone (3 x 200 mg/day)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 8280818

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole once daily (second 4 weeks)
Number of subjects: 313

Group type: COMPARATOR
Intervention: 20 mg omeprazole once daily (second 4 weeks)
Number of subjects: 313

Group type: COMPARATOR
Intervention: 20 mg omeprazole (4 weeks) then 20 mg (second 4 weeks)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole (4 weeks) then 40 mg (second 4 weeks)
Number of subjects: 313
Study: 3545418

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 189
Study: 30644785

Group type: EXPERIMENTAL
Intervention: CHO group (800 ml the evening before and 400 ml 2 hours before anesthesia)
Number of subjects: 58

Group type: COMPARATOR
Intervention: FAST group (overnight fasting)
Number of subjects: 58
Study: 30570132

Group type: EXPERIMENTAL
Intervention: Regorafenib alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regorafenib with concomitant esomeprazole
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regorafenib with esomeprazole 3 hours prior
Number of subjects: 14
Study: 28142059

Group type: EXPERIMENTAL
Intervention: CpG-ODN plus standard of care (SOC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 81
Study: 26380366

Group type: EXPERIMENTAL
Intervention: Psychoeducational program (12 weekly 1.5-hour sessions)
Number of subjects: 106
Study: 23412645

Group type: EXPERIMENTAL
Intervention: Learning Therapy (cognitive intervention program)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 156
Study: 21385479

Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube (NGT) 12 hours after operation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group with NGT remaining until first flatus
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Early removal of NGT
Number of subjects: 43
Study: 20545092

Group type: EXPERIMENTAL
Intervention: Retainers fitted to the test group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no retainers)
Number of subjects: 15
Study: 17324377

Group type: EXPERIMENTAL
Intervention: Tooth preparation for full crown and application of one‐step self‐etch adhesive (iBond Gluma inside)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sound intact teeth (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Teeth prepared for full crown and extracted within 2h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Teeth coated with one‐step self‐etch adhesive and extracted after 24h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Teeth coated with one‐step self‐etch adhesive and extracted after 48h
Number of subjects: 20
Study: 14963465

Group type: EXPERIMENTAL
Intervention: Alprostadil (Av group; n=11)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sildenafil (Sv group; n=12)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (P group; n=12)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Alprostadil (A group; n=10)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sildenafil (S group; n=10)
Number of subjects: 55
Study: 12351304

Group type: EXPERIMENTAL
Intervention: Capsicum plaster at K-D2 point
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Capsicum plaster at P6 point
Number of subjects: 160

Group type: COMPARATOR
Intervention: Inactive tape in control group
Number of subjects: 160
Study: 9835498

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (3 microgram/kg/min)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No dopamine
Number of subjects: 71
Study: 8528892

Group type: EXPERIMENTAL
Intervention: Spironolactone (type I glucocorticoid receptor antagonist), administered in increasing doses, orally.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered orally.
Number of subjects: 0
Study: 2909317

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg.h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg.h
Number of subjects: 60
Study: 30099833

Group type: EXPERIMENTAL
Intervention: Tranexamic acid solution (Transamin inj/sol 500 mg/5 mL) infused wet dressing for 20 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microneedling with tranexamic acid solution topical application followed by tranexamic acid solution infused dressing therapy every 15 days for four sessions
Number of subjects: 20
Study: 28976933

Group type: EXPERIMENTAL
Intervention: Black beans with rice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chickpeas with rice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plain white rice (control)
Number of subjects: 12
Study: 25639957

Group type: EXPERIMENTAL
Intervention: Simulation/Lecture Hybrid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lecture-Only Control
Number of subjects: 38
Study: 23477572

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy and radiation therapy (ADT‐RTH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiation therapy only (RTH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long-term ADT (n = 17)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short-term ADT (n = 11)
Number of subjects: 60
Study: 21684281

Group type: EXPERIMENTAL
Intervention: 1000 mg LX1031, given 4 times/day
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 250 mg LX1031, given 4 times/day
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 19538418

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Syntometrine
Number of subjects: 0
Study: 16684280

Group type: EXPERIMENTAL
Intervention: Silver-coated textiles (verum) worn directly on the skin for 2 weeks (35 patients + 2 dropouts)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cotton garments (placebo) worn directly on the skin for 2 weeks (22 patients + 9 dropouts)
Number of subjects: 68
Study: 15237068

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 23
Study: 11295717

Group type: EXPERIMENTAL
Intervention: RORS-G (glucose-based reduced osmolarity ORS)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RORS-R (rice-based reduced osmolarity ORS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: WHO-ORS (control)
Number of subjects: 95
Study: 9229021

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg body weight) on day 1 followed by amocarzine (3 mg/kg twice daily after meals) on days 8, 9, and 10
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ivermectin alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amocarzine alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ivermectin plus amocarzine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 100
Study: 8214507

Group type: EXPERIMENTAL
Intervention: Written pre-operative advice to stop smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3628823

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 30939898

Group type: EXPERIMENTAL
Intervention: 2013 Caprini risk assessment model (RAM)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Prospective department protocol
Number of subjects: 1078
Study: 28399902

Group type: EXPERIMENTAL
Intervention: Everolimus plus trastuzumab and paclitaxel
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel
Number of subjects: 303
Study: 25959570

Group type: EXPERIMENTAL
Intervention: Open posterolateral approach
Number of subjects: 23

Group type: COMPARATOR
Intervention: Closed anterior-posterior screw fixation
Number of subjects: 23